Harbinger Health Targets High-Mortality Cancers First With AI-Driven MCED Platform
Harbinger Is Laying Groundwork For Population-Wide Screening With Modular, Methylation-Based Testing
With a projected FDA submission within the next two to three years, Harbinger is prioritizing cancers based on lethality, prevalence, and unmet diagnostic need. Pancreatic and biliary cancers – often diagnosed at late stages and lacking established screening programs – will be among the initial targets.
